Our State-of-the-Art Review on Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses is now out on @JACCCardioOncology @JACCJournals 👇 https://t.co/4dovzIyTd0 Role of current multimodality imaging and future directions for their applications: 👥For

🎥 Here’s another episode of the #KnowTheAuthors series by #CardiovascularDiabetology @BioMedCentral aimed at highlighting the brilliant scientists behind the research. 📺In this episode, Dr. Ruijie Xie presents key insights from their study on cardiovascular risk prediction in

Full paper:

🔥 TCT Late Breaker in @JACCJournals: Are you ready for STEMI (OMI) networks 2.0? Queen of Hearts #AI reduces false activations by 5-fold while increasing sensitivity using only initial #ECG at triage!

Can #AI_ECG improve #STEMI activation pathways? Check out this interview with @RobertHermanMD discussing their #TCT2025 presentation and #JACCINT simultaneous publication👇🏽 https://t.co/DNbUNiijQt #CardioX #ACCFIT @JACCJournals @smithECGBlog

🆙 Check out the final part of the recent case involving a patient with acute decompensated heart failure due to multiple valvular heart diseases. After initial transfemoral TAVI, the patient was scheduled for a 45 days follow-up was and reassess the TR severity. 👉Discover how

Evaluating changes in absolute coronary flow & microvascular resistance in patients with AS undergoing TAVI: no changes immediately after TAVI. Over time, remodelling of the left ventricle is assoc. with increased hyperaemic perfusion https://t.co/jrAOn35JEK @EuroInterventio

🎯 To assess the association of glucometabolic parameters w/ T4aMI in NSTEMI pts undergoing PCI. 🩸Admission blood glucose (ABG), glycated hemoglobin (HbA1c), and stress hyperglycemia ratio (SHR) were tested. 👥 Consecutive NSTEMI patients undergoing PCI from the AMIPE

We’re delighted to present our clinical case from the Cardiology Unit at Sant’Andrea University Hospital, showcasing the multidisciplinary management of a patient with HFrEF and multiple Valvular Heart Diseases. A special thank you to the @iheartfunction (iHF) Educational

Delighted to share our new study on the link between air pollution, chromatin remodeling and brown fat dysfunction 🧡 Kudos to #SanjayRajagopalan and team! https://t.co/4KStRMCyB9 Press release from @uzh: https://t.co/rOsBBKE1H5 @CardioZurich @Unispital_USZ #CTEC

🎯To quantify the cardiorenal benefits of combination regimens with GLP-1RA, SGLT2i, and/or finerenone versus corresponding monotherapies. 👥Systematic review and meta-analysis of post hoc analyses of RCTs and 10 observational studies that met prespecified inclusion criteria.

This could have been a “boring” STEMI activation. What happens when you wait for ST elevation to develop?

In patients with severe aortic stenosis, absolute coronary flow and microvascular resistance do not change immediately or 6 months after TAVI. Yet, reverse LV remodelling is associated with improved hyperaemic perfusion, highlighting the dynamic interaction between coronary flow,

Remember the recent HFrEF case shared by Mustafa Goktug Erata & Mehmet Birhan Yilmaz? Part 2 is now available: the case of a 36-year-old male patient diagnosed with Becker muscular dystrophy. ➡️ Find out which strategy the team selected: https://t.co/40J96MaOe8

Australian ACS guidelines 2025 - The OMI has officially arrived! - ED Guidelines. https://t.co/92GWWoe61W

10 Issues for the Clinician in Tricuspid Regurgitation: 2025 ACC EDCP  https://t.co/WVeKnC4OiW  @JACCJournals @ACCinTouch @escardio @purviparwani @iamritu

📌Sub-analysis of the EmDia trial (NCT02932436) 🎯To assess changes in lipid profiles driven by Empagliflozin use in HF patients. 👥 Lipid analysis of blood plasma from 144 pts was conducted using 4D-LC-TIMS/IMS lipidomics and repeated after one and twelve weeks of treatment.

Case by Mustafa Göktuğ Erata & Mehmet Birhan Yilmaz: 🧔🏻36-yo with Becker Muscular Dystrophy, ADHF 🔎 Echo: HFrEF, dilated LV ⚠️ Meets ESC advanced HF + several AHA “I NEED HELP” markers → ~46.5% 1-yr mortality How would you treat this patient? https://t.co/40J96MaOe8

📌DAPAHEART trial: a single-center, 4-week, randomized (1:1 dapagliflozin 10 mg vs. placebo), double-blind, controlled study. 🎯To assess the long-term impact of dapagliflozin on CFR and EAT thickness in T2DM patients with CAD. 👥N=16 pts w/ T2DM+CAD were enrolled in the

The 2025 ESC/EACTS guidelines on the management of valvular heart disease have just been released, with an important update: the age threshold for the Heart Team to consider TAVI instead of surgical intervention has been lowered from 75 to 70 years in patients with tricuspid

🔓 For a limited time until August 16, we are offering free promotional access to a new article in #CJC! 🌐 This study links CT-derived extracellular volume fraction (ECV) to diastolic function changes before and after TAVI. Findings highlight ECV's potential as a biomarker for